Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney and thyroid cancers using its investigational therapy LP-184 (zirdafulven). The allowed claims cover the use of elevated expression of PTGR1, PTPN14 and ASPH to identify patients who may benefit from treatment with LP-184.
Lantern said its RADR artificial intelligence platform helped identify the biomarker signature used in the patent, supporting the development of a precision medicine approach for LP-184. The company reported a 45% disease control rate among patients treated at or above the effective therapeutic dose in its Phase 1a trial and plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio.
This patent allowance is significant because it strengthens Lantern's intellectual property around LP-184 and underscores the role of AI in identifying biomarkers that can guide patient selection, potentially improving treatment outcomes and reducing side effects. The biomarker-based approach aligns with the broader shift toward personalized medicine in oncology.
The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. More information is available at https://ibn.fm/LRGUo.
For the latest news and updates relating to LTRN, visit the company’s newsroom at https://ibn.fm/LTRN.
